From: Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
Parameters | OS | |||
---|---|---|---|---|
Total number of patients = 61 | ||||
HR (95%CI) | P-value | Adjusted HR (95%CI) | P-value | |
Elderly age (> 65 vs. ≤65 years) | 1.564 (0.690–3.545) | 0.284 | 1.376 (0.583–2.764) | 0.466 |
Advanced disease (stage III/IV vs. I/II) | 1.700 (0.982–3.114) | 0.086 | 1.300 (0.641–2.636) | 0.466 |
Tumor size (> 10 cm vs. ≤10 cm) | 1.418 (0.691–2.909) | 0.341 | 1.403 (0.586–3.356) | 0.447 |
Grade (3 vs. 2/1) | 2.144 (0.920–4.996) | 0.077 | 1.758 (0.625–4.945) | 0.285 |
Histological subtype (LMS vs. Others) | 0.968 (0.373–2.512) | 0.947 | 0.989 (0.362–2.699) | 0.982 |
Mitotic index (>15mitoses/10HPF vs. ≤15mitoses/10HPF) | 3.441 (1.649–7.181) | 0.001 | 3.283 (1.426–7.559) | 0.005 |
 | DFS | |||
Total number of patients = 42 | ||||
HR (95%CI) | P-value | Adjusted HR (95%CI) | P-value | |
Elderly age (> 65 vs. ≤65 years) | 1.404 (0.413–4.773) | 0.586 | 0.671 (0.138–3.266) | 0.621 |
Advanced disease (stage III/IV vs. I/II) | 1.267 (0.586–2.738) | 0.547 | 0.970 (0.352–2.676) | 0.953 |
Tumor size (> 10 cm vs. ≤10 cm) | 2.113 (0.853–5.235) | 0.106 | 4.071 (1.205–13.752) | 0.024 |
Grade (3 vs. 2/1) | 3.426 (1.014–11.569) | 0.047 | 4.121 (0.927–18.326) | 0.063 |
Histological subtype (LMS vs. Others) | 0.662 (0.263–1.667) | 0.381 | 1.414 (0.410–4.874) | 0.583 |
Mitotic index (>15mitoses/10HPF vs. ≤15mitoses/10HPF) | 2.687 (1.160–6.471) | 0.028 | 3.041 (1.127–8.204) | 0.028 |
Adjuvant regimen (Antracycline-based vs. other chemotherapy) | 0.783 (0.354–1.731) | 0.546 | 0.555 (0.172–1.794) | 0.325 |
 | 1st line PFS | |||
Total number of patients = 38 | ||||
HR (95%CI) | P-value | Adjusted HR (95%CI) | P-value | |
Elderly age (> 65 vs. ≤65 years) | 1.300 (0.493–3.433) | 0.596 | 0.927 (0.230–3.728) | 0.915 |
Tumor size (> 10 cm vs. ≤10 cm) | 0.679 (0.303–1.522) | 0.347 | 0.898 (0.270–2.986) | 0.861 |
Grade (3 vs. 2/1) | 0.471 (0.188–1.181) | 0.108 | 0.220 (0.047–1.032) | 0.055 |
Histological subtype (LMS vs. Others) | 0.662 (0.263–1.667) | 0.381 | 0.333 (0.087–1.282) | 0.110 |
Mitotic index (>15mitoses/10HPF vs. ≤15mitoses/10HPF) | 1.158 (0.512–2.621) | 0.752 | 1.463 (0.454–4.721) | 0.524 |
Adjuvant chemotherapy (Yes vs. no) | 1.324 (0.635–2.762) | 0.454 | 1.066 (0.337–3.375) | 0.914 |